Expand CELC Menu
CELC MENU

CELC Latest Press Releases

-- June 3, 2026 --

Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032 Globe Newswire 10:13 PM
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032 Globe Newswire 7:19 AM

-- June 2, 2026 --

Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer Globe Newswire 8:25 AM

-- June 1, 2026 --

Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026 Globe Newswire 8:30 AM

-- May 28, 2026 --

Celcuity To Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- May 14, 2026 --

Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients Globe Newswire 7:30 AM

-- May 7, 2026 --

Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call Globe Newswire 8:00 AM

-- May 1, 2026 --

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort Globe Newswire 5:03 PM

-- March 25, 2026 --

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- March 18, 2026 --

Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call Globe Newswire 8:00 AM

-- March 9, 2026 --

Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology Globe Newswire 5:42 PM

-- February 25, 2026 --

Celcuity To Participate in Upcoming Investor Conferences Globe Newswire 4:04 PM

-- February 12, 2026 --

Celcuity Appoints Charles Romp to its Board of Directors Globe Newswire 4:05 PM

-- February 4, 2026 --

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 Globe Newswire 7:05 AM

-- January 20, 2026 --

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes